Drug Profile
HF 0220
Alternative Names: 7β-hydroxy-epiandrosterone; 7β-OH-EPIA; HF0220Latest Information Update: 24 Jul 2015
Price :
$50
*
At a glance
- Originator Hunter-Fleming
- Developer Hunter-Fleming; Newron Pharmaceuticals
- Class 17 ketosteroids; Androstanols; Neuroprotectants; Testosterone congeners
- Mechanism of Action Antioxidants; Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 14 Sep 2010 HF 0220 is available for licensing worldwide as of 10 Sep 2010. http:///www.newron.com
- 23 Oct 2008 Adverse events data from a phase II trial in Alzheimer's disease released by Hunter-Fleming
- 31 Aug 2008 Hunter-Fleming completes a phase II trial in Alzheimer's disease in India, Sweden and the UK